Significant clinical response of activated carbon adsorbed-peplomycin against esophageal cancer: a pilot study.
Activated carbon particle adsorbed-peplomycin (PEP-CH) was administered to three patients who had advanced esophageal cancer and its clinical usefulness was evaluated. The PEP-CH was injected endoscopically into the tumor or the adjacent normal esophageal tissue. Case 1 and case 3 were treated by topical injection of PEP-CH with or without surgery and case 2 was subjected to the PEP-CH treatment with radiation. The barium swallow and endoscopic examination exhibited a marked tumor reduction in all the patients at the end of the PEP-CH treatment. Although a marked clinical response was seen, case 1 died of postoperative complication. Two patients were capable of oral food intake after the treatment, which had been impossible before the treatment. There were no serious adverse side effects caused by the PEP-CH treatment in all the patients. PEP-CH should prove valuable as a new form of chemotherapy for the treatment of esophageal cancer patients.
Kitamura
K
K
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Hagiwara
A
A
Sasabe
T
T
Kojima
O
O
Takahashi
T
T
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D002244:Carbon; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004337:Drug Carriers; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D004945:Esophagoscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017663:Peplomycin; D010865:Pilot Projects
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D001761:Bleomycin; D017663:Peplomycin; D002244:Carbon